Delgocitinib

• CAT Number: I014767
• CAS Number: 1263774-59-9
• Molecular Formula: C16-H18-N6-O
• Molecular Weight: 310.3592
• Purity: ≥95%
• Synonyms: Delgocitinib; LEO-124249; LEO124249; LEO 124249.
• Target: Stem Cell/Wnt
• IUPAC Name: 3-[(3S,4R)-3-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile
• InChI: 1S/C16H18N6O/c1-11-8-22(13(23)2-5-17)16(11)4-7-21(9-16)15-12-3-6-18-14(12)19-10-20-15/h3,6,10-11H,2,4,7-9H2,1H3,(H,18,19,20)/t11-,16-/m0/s1
• InChIKey: LOWWYYZBZNSPDT-ZBEGNZNMSA-N
• SMILES: C[C@H]1CN(C(=O)<wbr>CC#N)<wbr>[C@]12CCN(C2)<wbr>c3ncnc4[nH]ccc34

Delgocitinib, also known as LEO-124249, is an immunomodulator drug candidate.

Overview of Clinical Research

Originator: Japan Tobacco
Developer: Japan Tobacco; LEO Pharma
Class: Antiallergics; Antipsoriatics; Pyrimidines; Skin disorder therapies
Mechanism of Action: Janus kinase inhibitors
Orphan Drug Status: No
New Molecular Entity: Yes
Highest Development Phases: Phase III Atopic dermatitis